Full Text
Cost-Effectiveness of Crizotinib for Second and Third-Line Treatment of Non-Small Cell Lung Cancer in Ecuador

Abstract

Authors

V Freire M Cabezas E Salcedo A Albert

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×